Eisai Co. Ltd. (ESALF)

PNK: ESALF · Real-Time Price · USD

28.50

0.00 (0.00%)

At close: Apr 28, 2025, 10:25 AM

0.00% (1D)

Bid	26.26
Market Cap	8.04B
Revenue (ttm)	733.85B
Net Income (ttm)	32.65B
EPS (ttm)	1.44
PE Ratio (ttm)	19.79
Forward PE	n/a
Analyst	n/a

Ask	31.21
Volume	900
Avg. Volume (20D)	527
Open	30.00
Previous Close	28.50
Day's Range	28.50 - 30.00
52-Week Range	22.51 - 45.46
Beta	-0.16

About ESALF

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomni...

Sector Healthcare

IPO Date Apr 7, 2011

Employees 11,067

Stock Exchange PNK

Ticker Symbol ESALF

Website https://www.eisai.co.jp

Full Company Profile

News

2 weeks ago · reuters.com

EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat mild cognitive impairment in the early stages of Alzheimer's disease.

2 months ago · reuters.com

EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug

European Union's human medicines committee (CHMP) said on Friday it is not updating its opinion on Eisai and Biogen's Alzheimer's drug Leqembi, after it recommended its approval in November.

2 months ago · seekingalpha.com

Eisai Co., Ltd. (ESALF) Q3 2024 Earnings Call Transcript

Eisai Co., Ltd. (OTCPK:ESALF) Q3 2024 Earnings Call Transcript February 7, 2025 1:00 AM ET Company Participants Haruo Naito - Representative Corporate Officer & CEO Terushige Iike - Executive Vice Pre...